Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Preferred Stock Liabilities (2020 - 2021)

TScan Therapeutics (TCRX) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $159.4 million as the latest value for Q2 2021.

  • Quarterly Preferred Stock Liabilities rose 167.11% to $159.4 million in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $159.4 million through Jun 2021, up 167.11% year-over-year, with the annual reading at $59.7 million for FY2020, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q2 2021 was $159.4 million at TScan Therapeutics, roughly flat from $159.4 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $159.4 million in Q1 2021, with the low at $59.7 million in Q2 2020.